Google Alert - "LSD1 inhibitor" OR "sickle cell disease" · Scour

Agios Pharmaceuticals stock tumbles 25% after Novo data

Novo posts trial win for sickle cell disease drug (NVO:NYSE)

Phase 3 HIBISCUS: Etavopivat Cuts VOC Events, Improves Hemoglobin in SCD

Novo's late-stage sickle cell win piles pressure on competitors

Finally cracking KRAS as a druggable target

Novo Nordisk readies SCD drug for approval push after ph. 3 win

EHC proposes street dedication for local child | Neighbors News

Global Sickle Cell Disease Treatment Market to Reach USD 9.97

Novo Nordisk (NVO) Achieves Key Milestones in Etavopivat Sickle Cell Disease Trial

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and ...

Novo Nordisk meets both primary endpoints in phase III study with etavopivate in sickle cell anemia

Orkin Wins Breakthrough Prize in Life Sciences

Novo Nordisk's Etavopivat Hits Phase 3 Goals in Sickle Cell Disease , Regulatory Filing ...

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary ...

Etavopivat phase 3 success: Novo Nordisk (NVO) advances oral sickle cell therapy

Novo's oral sickle cell drug hits two bullseyes in pivotal trial

Novo Nordisk's Etavopivat Meets Co-primary Goals In Phase 3 HIBISCUS Trial In Sickle Cell Disease

Novo Nordisk's Sickle Cell Disease Drug Etavopivat Meets Co-primary Endpoints in Late-stage Trial

Novo candidate for rare blood disorder meets primary endpoint in phase III study

Fulcrum Therapeutics Q1 2026 Earnings Report

Log in to enable infinite scrolling